GlassScriptPhysician profile
Natalie Burks
NPI 1053304626
$7,238.76
in general payments reported to CMS, 2019-2025
38 companies · $517 in 2025
The $517 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,470 · 2022: $2,022 · 2023: $1,389 · 2024: $841 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.67 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,110.12 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $890.30 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $750.34 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $704.98 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $579.73 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $414.80 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $278.46 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $267.76 | 2021-2023 | Spravato, Xarelto |
| Amarin Pharma, INC. | $246.96 | 2021-2022 | |
| Dexcom, INC. | $222.69 | 2021-2023 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Mylan Specialty L.P. | $198.67 | 2021-2024 | Yupelri |
| Abbvie INC. | $158.61 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.70 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $138.51 | 2021-2022 | |
| Viiv Healthcare Company | $134.26 | 2024-2025 | Apretude |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Burks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.